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Holocarboxylase synthetase (HCS) catalyzes the binding of biotin to lysine (K) 
residues in histones H3 and H4. Histone biotinylation marks play important roles in the 
repression of genes and retrotransposons. Preliminary studies suggest that K16 in histone 
H4 is a target for biotinylation by HCS. Here we tested the hypothesis that H4K16bio is a 
real histone mark in human chromatin, and that H4K16bio is overrepresented in 
repressed gene loci and repeat regions. Polyclonal rabbit anti-human H4K16bio was 
generated and affinity purified. Using anti-H4K16bio and chromatin 
immunoprecipitation assays, we demonstrated that H4K16bio is overrepresented in repeat 
regions (pericentromeric alpha satellite repeats; long terminal repeats (LTR) compared 
with euchromatin promoters. H4K16bio was also enriched in the repressed interleukin-2 
gene promoter. The enrichment at LTR22 and promoter 1 of the sodium-dependent 
multivitamin transporter (SMVT) depended on biotin supply; the enrichment was greater 
in biotin-supplemented cells compared with biotin-normal and biotin-deficient cells. The 
 
 
enrichment of H4K16bio at LTR15 and SMVT promoter 1 was significantly lower in 
fibroblasts from an HCS-deficient patient compared with an HCS wild-type control. We 
conclude that H4K16bio is a real phenomenon and that this mark, like other biotinylation 
marks, plays a role in the transcriptional repression of repeats and genes.  
HCS catalyzes the covalent binding of biotin to carboxylases, in addition to its role 
as a histone biotinyl ligase. Biotinylated carboxylases play crucial roles in the 
metabolism of fatty acids, amino acids, and glucose. HCS null individuals are not viable 
whereas HCS deficiency is linked to developmental delays and phenotypes such as short 
life span and low stress resistance. Here, we developed a 96-well plate assay for high-
throughput analysis of HCS based on the detection of biotinylated p67 using IRDye-
streptavidin and infrared spectroscopy. We demonstrated that the catalytic activity of 
rHCS depends on temperature and time, and proposed optimal substrate and enzyme 
concentrations to ensure ideal measurement of rHCS activity and its kinetics. 
Additionally, we demonstrated that this assay is sensitive enough to detect biotinylation 
of p67 by endogenous HCS from Jurkat lymphoid cells.  
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Biotin 
 
Biotin, also known as vitamin B7 or H,  is a water-soluble vitamin involved in many 
metabolic pathways in mammals (1). Chemically, biotin is a monocarboxylic acid 
consisting of a ureido group, thiophane heterocyclic ring,   and a valeric acid side chain 
(1-3) (Fig. 1).   
 
Figure 1. Biotin structure  
 
Humans cannot synthesize biotin but depend on dietary biotin supply (4).  Biotin can 
be found in high concentration in egg yolk, cow milk, liver and some vegetables (5). For 
absorption of dietary biotin, the protein-bound biotin in foods has to be converted to free 
biotin by the action of gastrointestinal proteases, peptidases, and biotinidase (1, 5). The 
uptake of free biotin by the cells is mediated by the sodium-dependent multi-vitamin 
transporter (SMVT) which also transports  pantothenic acid and lipoate (5, 6). 
Monocarboxylate transporter 1 (MCT1) has also been reported to participate in the 
transport of biotin, but its function is restricted to lymphoid cells (7, 8) (Fig. 2).  
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Figure 2. Biotin transport and metabolism, modified from (9). B: biotin, SMVT: 
sodium multivitamin transporter, MCTI: monocarboxylate transporter 1, PCC: propionyl-
CoA carboxylase,  ACC1: cytoplasmatic acetyl-CoA carboxylase α, ACC2: 
mitochondrial acetyl-CoA carboxylase  β, PC:  pyruvate carboxylase, MCC:  and 3-
methylcrotonyl-CoA carboxylase.   
 
 Biotin plays important roles in the metabolism of glucose, amino acids and fatty 
acids due to its role as a coenzyme in the metabolism of propionyl-CoA carboxylase 
(PCC), cytoplasmatic acetyl-CoA carboxylase 1 (ACC1), mitochondrial acetyl-CoA 
carboxylase  2 (ACC2), pyruvate carboxylase (PC) and 3-methylcrotonyl-CoA 
carboxylase (MCC) (10, 11).  Additionally, it has been shown that biotin is involved in 
gene regulation by its attachment to histones in the chromatin (10).  
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Holocarboxylase Synthetase (HCS)  
 
HCS functions as a biotin-ligase for carboxylases and histones (Fig. 3). This enzyme 
is a 726 amino acid protein with an estimate molecular weight of 81 kDa (12).  Four 
domains in human HCS have been identified: the N-terminal domain, C-terminal domain, 
central domain, and linker domain (13) (Fig-3). The N-terminal and C-terminal domains  
have been proposed to participate in substrate recognition  while  central domain has the  
binding sites for ATP and biotin (13).  The linker domain has been associated with the  
flexibility of HCS  to interact with other substrates for biotinylation (13). It has been 
reported that HCS localizes in mitochondria and cell nuclei; however due to  HCS lacks 
of nuclear localization sequence and DNA binding motif (14) its localization in the 
nucleus is still controversial (15, 16).     
 
 
Figure 3. Four domains in human HCS: N-terminal domain, central domain (CD) 
containing biotin and ATP binding sites, linker domain (L), and C-terminal domain (CT) 
(13). 
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HCS catalyzes biotinylation of carboxylases and histones in a two-step ATP-
dependent reaction (17). In the first step, biotinyl 5’-AMP (B-AMP) is generated; in the 
second step, biotin is transferred from B-AMP to the lysine residue in the 
apocarboxylases and histones (15).  It has been demostrated that HCS acts as its ortholog 
BirA ligase found in Escherichia coli. BirA ligase  participates in the biotinylation of 
biotinoyl carboxyl carrier protein (BCCP)  and its  amino acid sequence is 21% identical  
with HCS (18-21).   
The important role of HCS in biotinylation of histones has been confirmed  in 
various studies (22, 23). Camporeale et al. compared the ability of  SMVT mutants and 
HCS-deficient Drosophila melanogaster  to biotinylate histones.  The results 
demonstrated that HCS knockdown is associated with a decrease in biotinylation of 
histones due to the low biotin-ligase activity,  rather than the low  levels of biotin in the 
cells  (22). Importantly, Baolong et al. recently reported that HCS interacts physically 
with histone H3 to mediate binding to chromatin and subsequent biotinylation of K9 and 
K18 in histone H3 (24).  
For the study of the activity of HCS, a peptide spanning C-terminal  67 amino acids 
of PCC, known as p67,  has been used as  substrate  for biotinylation by HCS in previous 
studies (25-27).  p67 contains the biotin-binding consensus sequence (AMKM)  for biotin 
binding (26, 27). In this thesis p67 was used as a substrate for the development of the 96-
well plate assay for high-throughput screening  of HCS activity (see Chapter 3).  
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Biotinidase (BTD) 
BTD belongs to the nitrilase superfamily of enzymes which consists  of 12 families 
of amidases, N-acyltransferases, and nitrilases (28). BTD shares significant sequence 
similarities with some members of the nitrilase superfamily such as vanins -1, -2 and -3 
(29).  In mammalian cells,   26% of the cellular biotinidase activity resides in the nucleus 
(30) although  its nuclear localization has been disputed subsequently (31). The BTD 
gene localizes in chromosome 3p25  and its structure has been determined (32). The BTD 
gene contains four exons: A125-44, B45-309, C310-459 and D460-1961. Exons B through D 
code for the mature protein (31) while the 5’-flanking region of exon 1 contains a 
CCAAT element, three initiator sequences, an octamer sequence, three methylation 
consensus sites, two GC boxes, and one HNF-5 site but  lacks a TATA element (32). 
The classical role of BTD in metabolism is to hydrolyze biocytin (biotinyl- ε -lysine) 
generated in the breakdown of biotin-dependent carboxylases (33). Thus, free biotin is 
released and recycled in holocarboxylase synthesis and used in other processes (10).  The 
role of BDT in biotinylation of histones has been demonstrated based on in vitro studies 
with purified histones  (33). It was proposed that BTD might mediate the binding of 
biotin to histones  by the hydrolysis of  biocytin forming a biotinyl-thioester intermediate 
(cysteine-bound biotin) near its active site. Thus,   biotin is bound to the biotinyl moiety 
from the cysteine residue  and transfer  to the ε-amino group of the lysine in histones  (20, 
33).   
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Evidence has been provided that BTD might catalyze debiotinylation of histones 
(34). It was proposed that variables such as microenviroment in chromatin, 
posttranscriptional modifications and alternative splicing might determine whether BTD 
acts as a biotinyl histone transferase or histone debiotinylase (1). For example covalent 
modifications such as glycosylation might influence the enzyme activity to biotinylate or 
debiotinylate  histones (34, 35).  In the same way, the presence of cofactors such as high 
concentrations of biocytin might favor and increase the rate of biotinylation of histones 
(34).   
  
Apocarboxylases 
Biotin  serves as a covalently bound coenzyme for  propionyl-CoA carboxylase 
(PCC), cytoplasmatic acetyl-CoA carboxylase 1 (ACC1), mitochondrial acetyl-CoA 
carboxylase  2 (ACC2), pyruvate carboxylase and 3-methylcrotonyl-CoA carboxylase 
(MCC)  (10, 11). Biotin is covalently attached to the ε-amino group of a distinct  lysine 
residue  in holocarboxylases (inactive enzyme) by holocarboxylase synthetase (HCS) (15, 
25, 36). 
In the cell, PCC localizes in the mitochondria and is required for catabolism of the 
amino acids  isoleucine, threonine, methionine, valine,  and  odd chain fatty acids (10). It 
is also involved in the carboxylation of propionyl-CoA to D-methylhalonyl-CoA (37, 38). 
The last 67 amino acids of PCC C-terminus domain  has been used as an important  tool 
for study of  the  bioactivity of HCS because its properties as a  well-established HCS 
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substrate (25, 26). This polypeptide, known as p67, contains the biotin-binding consensus 
(AMKM) sequence (26, 27).   
ACC1 and ACC2 catalyze the binding of bicarbonate to acetyl CoA, generating 
malonyl CoA (10). These two enzymes share approximately 70% of the amino acid 
sequence but differ in cellular localization (10, 39, 40). ACC1 participates in fatty acid 
synthesis in cytoplasm, while ACC2 participates in the regulation of fatty acid oxidation 
in mitochondria (10).   
PC participates in the carboxylation of pyruvate to oxalacetate in gluconeogenesis 
(10, 41), and  MCC participates in the catabolism of the leucine by converting 3-
methylcrotonyl-CoA to 3-methylglutaconyl-CoA (42).  
 
Biotin and Gene expression 
 
Interleukin-2   
Human lymphoid cells normally secret cytokines in response to stimulation of the 
immune system (43, 44). Interleukin-2 (IL-2) is a cytokine secreted when a cell surface 
receptor interacts with its specific ligand molecule causing a rapid hydrolysis of inositol 
phospholipids to diacylglicerol and inositol phosphates by phospholipase C (PLC) (43, 
44). Diacylglycerol then activates protein kinase C (PKC) and inositol phosphate, thus,  
triggering the release and mobilization of Ca++.  This process results in additional 
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cellular responses that mediate T-cell activation, and therefore  IL-2 production and 
secretion  (43, 44).  
In vitro, phorbol 12-myristate 13-acetate (PMA) has been used to stimulate 
production of IL-2. PMA has an analogous structure to diacylglycerol, thus, it activates 
PKC and T-cells to stimulate IL-2 production. A combination of PMA with 
phytohemaglutinin  (PHA), a co-stimulator that binds non-specifically to the cell surface 
receptor complex, can be used to increase  IL-2  expression (43, 44).  
Previous studies have provided  evidence that biotin plays an important role in 
immune function (45-50).  For instance, biotin supplementation has been reported to 
decrease the secretion  of interleukin-2 and interleukin-1β by PBMC (51). In addition,  
the association  of biotin with repression of the gene coding for IL-2 (52, 53)  was 
reported by  Camporeale at el when they  demonstrated that biotinylation of K12 in 
histone H4  represses  interleukin-2 gene (52). Likewise, Pestinger at el, reported similar 
observations  with the biomarks H3K9bio, H3K18bio and H4K8bio (53).  
 
Transposable elements: Long terminal repeats (LTR) 
Transposable elements are sequences in the DNA that can change their positions 
within the genome of a single cell in a process called transposition (54-56). Transposition 
has been associated with mutations and abnormal patterns in gene expression (57, 58). In 
mammals, transposable elements type I constitute approximately 42% of the human 
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genome and are divided into two groups: the long terminal repeats (LTR) and the long 
interspersed nucleotide elements (LINE) (59). Additionally,  LTRs are grouped in intact 
retrotransposons LTR and solitary LTR (59).  In the intact retrotransposons LTR,  the 
viral genes gag, pol and enw  are flanked by two repeat regions: 5’-LTR and 3’-LTR, and 
the expression of retroviral genes is regulated by 5’-LTR (59, 60). In the case of solitary  
LTR, the retroviral genes have been deleted by recombination of the LTR ; (54, 57-60), 
and therefore they are  unable to produce viral proteins.  However, they may have 
retained their promoter activity; which could cause abnormal patterns of   host gene 
expression (57, 58).  
Previous studies have suggested that biotinylation plays an important role in the 
silencing of genes coding for retrotransposons (59).  It was found, that biotinylation of 
lysine 12 in histone H4  (H4K12bio) and lysine 9 in histone H2 (H2AK9bio) represses 
retrotransposon transcription in human and mouse cell lines (59). Additionally, 
biotinylation of  lysines 9 and 18  in histone H3 (H3K9bio and H3K18bio),  and lysine 8 
in histone H4 (H4K8bio)  were associated with LTR repression in human lymphoid cells 
(53).  
15 
 
Biotin Deficiency  
 
Symptoms of biotin deficiency can be found in  individuals with insufficient dietary 
intake;  mutations in BTD, HCS, SMVT or carboxylases (10),  and in individuals that  
consume large amounts of raw egg white, lipoic acid, excessive alcohol, or are on term-
long drugs treatments (10, 61, 62).  Symptoms can go from  feeding difficulties, 
hypotonia, vomiting, alopecia, ataxia, conjunctivitis, periorifitial dermatitis and skin 
infections to critical progressive loss of consciousness, coma and death (12, 62, 63). Its 
diagnosis is suggested by the increase in the excretion of organic acids such as lactate  
and  3-hydroxyisovaleric acid in the urine,  and its treatment consists in  the 
administration of pharmacological oral doses of biotin (15).   
Mutations in  HCS lead to the inability to form active holocarboxylases resulting in  
multiple carboxylases deficiency (MCD)  (10, 62); while the defects of BTD has effects 
in the recycling of biotin from degraded carboxylases and the release of biotin from 
dietary proteins (10). Importantly, previous studies suggested that half of the pregnant 
women in USA experience marginal biotin deficiency (64-68); however, its impact as 
teratogenic effect has not been demonstrated in humans. On the contrary, studies with 
mice showed fetal malformations such as cleft palate and micromelia (69, 70).   
Studies with Drosophila melanogaster suggest that biotin deficiency caused by 
mutant HCS resulted in a decrease of life span (up to 32%) and stress survival (22, 71). 
Moreover, it was demonstrated that these effects were caused by the deficiency of histone 
biotinylation rather than carboxylases. In addition, it was proposed that HCS deficiency  
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affected gene expression in these cells  due to chromatin modifications. The results 
showed a 50%  decrease in  the expression of  77 genes associated with defense response, 
and  a 100% increase of  124 genes involved in signal transduction, transport and cell 
death (22, 71).   
 
Histones and Chromatin 
Histones are small basic proteins (11-22 kDa) involved in the folding of the DNA 
into chromatin (72).  They  are modified by the covalently binding of biotin to lysine 
residues by holocarboxylase synthetase (73, 74). There are five major classes of histones 
in chromatin: H1, H2A, H2B, H3 and H4 (74).  Histones H2A, H2B, H3 and H4 form an 
octamer of core histones with one H3-H3-H4-H4 tetramer and two H2A-H2B dimers 
while histone H1 is the linker histone bound to the DNA in between two nucleosomes  
(Fig. 4) (75). Importantly, histones are positively charged proteins due to the presence of 
a large number of lysine and arginine residues (20-25% of the amino acids).  The 
electrostatic interaction between the negative charge of DNA and the positive charge of 
histones stabilizes the formation of the nucleosomal core particle (74).   
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Figure 4. Nucleosome structure. Octamer of histones. 
http://www.statemaster.com/encyclopedia/Nucleosome 
 
Covalent histones modifications  
Histones are target for reversible covalent modifications such as acetylation, 
methylation, phosporylation, poly (ADP-ribosylation) and biotinylation. These 
modifications have distinct functions in gene expression, chromatin remodeling,  
transcriptional regulation, and DNA repair (15, 76-78). For example, acetylation of lysine 
residues has been associated with transcriptional activity of genes (79). Acetylation 
neutralizes the charges of lysine residues  allowing dissociation of histones from DNA. 
This dissociation allows RNA polymerase  to access the promoter region and begin 
transcription (79). In contrast, hypoacetylation has been associated with repression (79).  
Methylation, may be associated with transcriptional activation or repression. For 
instance, methylation of K9 in histone H3 is associated with heterochromatin (inactive 
genes), whereas   methylation of Lys K4 in histone H3 is associated with active 
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transcription (80). Phosphorylation and poly (ADP-ribosylation) are associated with 
signaling and  DNA repair (81). 
Biotinylation of Histones 
In previous studies, 11 biotinylation sites in histones have been identified: K9, K13, 
K125, K127 and K129 in histone H2A (82); K4, K9, K18 and perhaps K23 in histone H3 
(72); and K8 and K12 in histone H4 (83) (Fig.  5).  
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Figure 5. Covalent modifications in human histones,  modified from (2). 
Abbreviations: A: acetate, B: biotin, M: methyl, P: phosphate, U: ubiquitin. 
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Biotinylation of histones plays an important role  in the cellular response to DNA 
damage (84), cell proliferation (73), and mitotic condensation of chromatin (85).  In fact, 
H4K12bio has been associated with gene silencing (52) and repression of transponsable 
elements (86).  
     The use of specific antibodies for studies of histone biotinylation has become an 
important tool for studying their biological functions (82, 83, 87, 88). In previous studies 
specific antibodies to H4K12bio were generated  to investigate  its relative enrichment in 
repeat regions such as pericentromeric alpha satellite repeats (52) and telomeres (89) , as 
well as  its association  with the repression of SMVT transporter gene and 
retrotransponsons (59, 90).  Pestinger et al.  also used specific antibodies to report the 
enrichment of H3K9bio, H3K18bio and H4K8bio in pericentromeric alpha satellite 
repeats, long terminal repeats, and promoter 1 of the SMVT gene (53). The biological 
functions of the other  biotinylation sites are still unknown.  Mass spectrometry studies 
provided preliminary evidence for the existence of a novel biotinylation site, H4K16bio, 
in addition to the 11 known biotinylation sites, but  with inconclusive results (87).  
    This master thesis focused on two major projects. First, I discovered a new histone 
biotinylation site, K16-biotinylated histone H4, and generated first insights into its 
biological functions in gene regulation and chromatin structure (see chapter 2).  Second, I 
developed  a 96 well-plate assay for high-throughput screening of HCS (see chapter 3). 
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CHAPTER 2 
 
K16-BIOTINYLATED HISTONE H4 IS OVERREPRESENTED IN 
REPEAT REGIONS AND PARTICIPATES IN THE REPRESSION 
OF TRANSCRIPTIONALLY COMPETENT GENES IN HUMAN 
JURKAT LYMPHOID CELLS 
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  Introduction 
 
Histones mediate the folding of DNA into chromatin (1). Amino acid residues in the 
N-terminal tails and, to a lesser extent, other domains of histones are targets for covalent 
modifications such as acetylation and methylation (2). These posttranscriptional 
modifications play important roles in gene regulation, chromatin remodeling, mitosis, and 
DNA repair. For example, lysine (K)-9 acetylated histone H3 (H3K9ac) and K4-
trimethylated histone H3 (H3K4me3) are overrepresented in transcriptionally active 
euchromatin, whereas hypoacetylated histones and K9-dimethylated histone H3 
(H3K9me2) are overrepresented in heterochromatin and repressed genes. 
Wolf and co-workers provided evidence that histones are also modified by covalent 
attachment of the vitamin biotin, based on in vitro studies with purified histones and the 
histone biotinyl ligase, biotinidase (3). Subsequently, biotinylated histones were detected 
in chromatin from human and other metazoans by using radiotracers, streptavidin, anti-
biotin, biotinylation site-specific antibodies, and mass spectrometry {(4-9), T. Kuroishi et 
al., unpublished}. The majority of biotinylation takes place at K4, K9, K18, and perhaps 
K23 in histone H3 (10, 11), and K8 and K12 in histone H4 (6), but a weak biotinylation 
signal can also be detected in histone H2A (4, 12). These previous studies also suggest 
that holocarboxylase synthetase (HCS) is more important than biotinidase for catalyzing 
biotinylation of histones in vivo (7, 11, 13). Phenotypes of HCS knockdown include a 
short life span and low heat survival in Drosophila melanogaster (7) and aberrant gene 
regulation in humans (14, 15). 
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Biotinylation of histones is a fairly rare event, i.e., less than 0.1% of histones in bulk 
extracts are biotinylated in samples of human origin {(16), T. Kuroishi et al., 
unpublished}. However, the comparably low level of global histone biotinylation is not 
representative of the level of biotinylation in confined regions of chromatin. For example, 
about one of three histone H4 molecules in telomeric repeats is biotinylated at K12 (17). 
Biotinylation of histones has important functions in gene repression and genome stability. 
Previous studies suggest that K9- and K18-biotinylated histone H3 (H3K9bio, 
H3K18bio) and K8- and K12-biotinylated histone H4 (H4K8bio, H4K12bio) are enriched 
in repeat regions and participate in gene repression (14, 15, 17-19). The abundance of 
histone biotinylation marks depends on both biotin supply and HCS activity (14, 15, 19); 
low abundance of H4K12bio in biotin- or HCS-deficient humans, mice, and flies de-
represses retrotransposable elements, thereby increasing genome instability and possibly 
cancer risk (14). 
Preliminary mass spectrometry studies provided evidence that histone H4 is also 
biotinylated at K16 (H4K16bio) (12). Here, we tested the hypotheses that H4K16 is a true 
biotinylation mark in human chromatin and that H4K16bio, like other biotinylation 
signatures, is overrepresented in repeat regions and participates in the repression of 
transcriptionally competent chromatin.  
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Materials and Methods 
 
Cell culture: 
 
Jurkat human lymphoma cells (ATCC, Manassas, VA) were cultured in commercial 
RPMI-1640 (Thermo Scientific, Waltham, MA) using standard cell culture techniques 
(20). Regular commercial RPMI-1640 contains 820 nmol/l biotin, which is >3,000 times 
the biotin concentration in human plasma (21). In some experiments, cells were cultured 
in biotin-deficient (0.025 nmol/l biotin), biotin-physiological (0.25 nmol/l biotin), and 
biotin- pharmacological (10 nmol/l biotin) media for 12 d prior to analysis (20). These 
concentrations represent levels observed in plasma from biotin-deficient individuals, 
biotin-normal individuals, and individuals taking over-the-counter biotin supplements 
(21, 22). Biotin-defined media were prepared using customized RPMI-1640 and biotin-
depleted fetal bovine serum (20). Efficacy of treatment was confirmed by probing 
biotinylated carboxylases with IRDye-streptavidin (19). Where indicated, expression of 
interleukin-2 (IL-2) was stimulated by treating Jurkat cells with phorbol-12-myristate-13-
acetate (PMA) and phytohemaglutinin (PHA) (20) for 3 h.  
Human WG2215 HCS-deficient skin fibroblast (Montreal Children’s Hospital Cell 
Repository, Montreal, Canada) were cultured in Dulbecco’s modified Eagle’s medium 
containing 10 nmol/l biotin to investigate effects of HCS deficiency on histone 
biotinylation (19); human HCS wild-type IMR-90 fibroblasts (ATCC, Manassas, VA) 
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were used as controls. HCS activity in IMR-90 and WG2215 fibroblasts was assessed by 
using biotinylated carboxylases as markers in streptavidin blots (19). 
 
Antibodies: 
 
Rabbit anti-human H4K16bio was generated as described (6). Briefly, an H4-based, 
K16-biotinylated synthetic peptide (GGAK(bio)RHRKVLRD, Anaspec; San Jose,CA) 
was conjugated to keyhole limpet hemocyanin (KLH; Pierce, IL) and used as antigen for 
injection into New Zealand rabbits. Specificity tests revealed that the anti-serum cross-
reacted with K16-acetylated histone H4, using the synthetic peptide 
GGAK(ac)RHRKVLRD (H4K16ac) as a target (data not shown). To eliminate cross-
reactivity with H4K16ac, the antiserum was affinity purified by using immobilized 
peptide H4K16ac and HiTrap™ NHS-Activated Sepharose™ High Performance Column 
(cat.# 17-0717-01, GE Healthcare; Piscataway, NJ) following the manufacturer’s 
protocol. Identity and purity of all synthetic peptides were confirmed by mass 
spectrometry and HPLC, respectively, by the manufacturer.  
Biotinylation site specificity of anti-H4K16bio was confirmed by using synthetic 
histone-based peptides, histone bulk extracts, biotin-depleted histones, and competition 
studies as described before (6). Equal loading and transfer was confirmed by staining 
membranes with Ponceau S (19). 
Polyclonal rabbit anti-human antibodies to H4K16bio, H4K12bio and H3K9me2 
were generated in a commercial facility (Cocalico Biologicals, Reamstown PA) as 
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described (6, 10, 19), while antibodies to the C-terminus in histone H3 (ab1791) and 
H3K9ac (ab10812) were purchased from Abcam (Cambridge, MA). H3K9me2 and 
H4K12bio were used as gene repression and heterochromatin marks, whereas H3K9ac 
was used as a euchromatin mark. Rabbit polyclonal anti-human pyruvate carboxylase 
(PC) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and PC in 
transblots was probed as described before (19). 
 
Micro chromatin immunoprecipitation (µChIP) assay: 
 
The enrichment of H4K16bio in distinct loci in human chromatin was assessed by 
micro chromatin immunoprecipitation (µChIP) assay as described (19, 23) with the 
following modifications. Chromatin form Jurkat cells was precipitated using 14µl of anti-
H4K12bio and anti-H3K9me2, and 28 µl of anti-H4K16bio sera. 
 
Quantitative real-time PCR (qRT-PCR): 
 
The abundance of DNA in immunoprecipitated chromatin was quantified by qRT-
PCR using Perfecta SYBR Green FastMix ROX (VWR; West Chester, PA) and PCR 
primers for long terminal repeats (LTR) 15 and 22, pericentromeric alpha satellite repeats 
in chromosome 4, and promoters in genes coding for IL-2, sodium-dependent 
multivitamin transporter (SMVT), aldehyde dehydrogenase (ADH) 5, and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (19). Amplicons were quantified 
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using the cycle threshold values method (24). GAPDH was used to normalize qRT-PCR 
data for amplification efficiency. The relative enrichment of histone marks in precipitated 
chromatin was calculated as percent of input DNA (25, 26); enrichment data were 
normalized for nucleosomal occupancy by precipitating samples with an antibody to the 
(non-modified) C-terminus in histone H3. Non-specific rabbit IgG (Santa Cruz, Santa 
Cruz, CA) was used as a control for background noise and precipitated negligible 
amounts of chromatin (<5% of compared with anti-H4K16bio), consistent with previous 
observations (19). 
The abundance of mRNA coding for IL-2, LTR22, and SMVT was quantified using 
Absolute QPCR SYBR Green fluorescein mix (ABgene; Rochester, NY) as described (6, 
19).  
 
Statistical analysis: 
Bartlett’s test was used to test for homogeneity of variances (27). Data were log 
transformed if variances were heterogeneous. Significance of differences among more 
than two groups was tested by one-way ANOVA and Fisher’s Protected Least Significant 
Difference procedure for post hoc testing. Student’s paired t-test was used for pairwise 
comparisons of data from Jurkat cells before and after stimulation  with PMA and PHA. 
µChIP data from WG2215 and IMR-90 fibroblasts were not normally distributed and 
were analyzed by using the Mann-Whitney U test. StatView 5.0.1 (SAS Institute, Cary 
NC, USA) was used to perform all calculations. Differences were considered statistically 
significant if P < 0.05. Data are expressed as mean ± S.D. 
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Results 
Specificity of anti-H4K16bio: 
Affinity-purified anti-H4K16bio is specific for its designated target, based on the 
following lines of observations. In a first series of experiments we compared the affinity 
of anti-H4K16bio for the synthetic peptides H4K16bio and H4K16ac (Fig. 1A). Purified 
anti-H4K16bio produced a strong signal with peptide H4K16bio (lane 1), but not signal 
with peptide H4K16ac (lane 2). The presence of biotinylation and acetylation marks was 
confirmed by probing transblots with IRDye-streptavidin (lanes 3 and 4) and anti-
H4K16ac (lanes 5 and 6). Equal loading and transfer was confirmed by staining 
transblots with Ponceau S (lanes 7and 8). Note the non-specific signal in the Ponceau S-
stained membrane, caused by interference of the dye in the sample loading buffer 
(denoted “L”). 
In a second series of experiments, we assessed the biotinylation site specificity of 
anti-H4K16bio by comparing its binding to synthetic peptides biotinylated at K8 (N6-
15bioK8), K12 (N6-15bioK12), or K16 (N13-24bioK16), where subscripts denoted amino 
acid residues in histone H4; the non-biotinylated peptide N1-19 was used as negative 
control. Anti-H4K16bio produced a strong signal with peptide H4K16bio, whereas the 
signals with peptides H4K8bio and H4K12bio were hardly detectable (Fig. 1B, lanes 1-
3); no signal was detectable with non-biotinylated peptide (lane 4). Equal biotinylation of 
synthetic peptides was confirmed by probing transblots with IRDye-streptavidin (Fig. 1C, 
lanes 1-3); equal loading of the non-biotinylated peptide N1-19 was confirmed 
gravimetrically. 
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Figure 1. Validation of anti-H4K16bio. (A) K16-biotinylated and –acetylated peptides 
were probed with anti-H4K16bio, IRDye-streptavidin, anti-H4K16ac, and Ponceau S. (B) 
Synthetic H4-based peptides biotinylated at K8 (N6-15bioK8), K12 (N6-15bioK12), and 
K16 (N13-24bioK16), and non-biotinylated peptide N1-19 were probed with anti-H4K16bio. 
(C) Peptides H4K8bio, H4K12bio, and H4K16bio from panel B were probed with 
IRDye-streptavidin. (D) Bulk extracts of Jurkat cell histones were probed with IRDye-
streptavidin, anti-H4K16bio and pre-immune serum; “-“ denotes biotin-depleted histone 
samples. (E) Bulk extracts of Jurkat cell histones were probed with anti-H4K16bio in the 
presence of increasing amounts of synthetic peptides H4K16bio, H4K12bio, and 
H4K8bio. The control sample (“C”) was assayed in the absence of  peptide competitors. 
Some gels were electronically re-arranged to facilitate comparisons. Abbreviations: L, 
loading buffer; P, peptide. 
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In a third series of experiments, we identified H4K16bio in histone bulk extracts 
from Jurkat cells. First, we probed histones with streptavidin to demonstrate that the 
majority of biotinylation marks resides in histones H3 and H4, and that biotinylation of 
histones H1, H2A, and H2B is quanitatively minor (Fig. 1D, lane 1), consistent with our 
previous results (4). Equal loading and integrity of proteins was confirmed by staining 
with Commassie blue (not shown). When histones were probed with anti-H4K16bio the 
antibody produced a signal only with histone H4, but not with other classes of histones 
(lane 2). This signal was specifically caused by the biotinylated fraction of histone H4, 
because biotin-depleted histones did not produce a signal (lane 3). When transblots were 
probed with pre-immune serum, no signal was detectable (lane 4). 
In a fourth and final series of antibody testing, bulk extracts of Jurkat cell histones 
were probed with anti-H4K16bio in the presence of increasing amounts of synthetic 
peptides. As expected, peptide H4K16bio outcompeted histone H4 for binding by anti-
H4K16bio compared with peptide-free control (Fig. 1E, lanes 1-5). In contrast, peptides 
H4K12bio (lanes 6-9) and H4K8bio (lanes 10-13) did not compete for binding. 
 
Relative enrichment of H4K16bio at selected genomic loci: 
 
H4K16bio is overrepresented in pericentromeric alpha satellite repeats 
(heterochromatin) in chromosome 4 compared the promoters of the two euchromatin 
genes GAPDH and ADH5 in Jurkat cells (Fig. 2A); the enrichment of H4K16bio in the 
promoters of the two euchromatin genes GAPDH and ADH5 produced comparable 
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signals. The known repression marks H4K12bio and H3K9me2 (18, 19) were used as 
positive controls and showed a pattern similar to that of H4K16bio (Fig. 2B and C). In 
contrast, the known activation mark H3K9ac (negative control) was greatly enriched in 
euchromatin promoters compared with pericentromeric alpha satellite repeats (Fig. 2D).  
 
Figure 2. H4K16bio is overrepresented in pericentromeric alpha satellite repeats 
(heterochromatin) compared with promoters in euchromatin. Chromatin was 
immunoprecipitated using antibodies to H4K16bio, H4K12bio, H3K9me2, and H3K9ac, 
and qRT-PCR was used to quantify the relative enrichment of alpha satellite repeats in 
chromosome 4 (Chr4alpha), and promoters of the GAPDH and ADH5 genes. Bars 
without a common letter are significantly different (n = 4, P < 0.05) 
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H4K16bio was overrepresented in the transcriptionally repressed promoter in the IL-
2 gene prior to stimulation with PMA and PHA compared with 3 h after activation with 
PMA and PHA (Fig. 3A). qRT-PCR was used to confirm efficacy 
of de-repression of the IL-2 gene by treatment with PMA and PHA (arbitrary units): 1.0 ± 
0.2 before stimulation vs. 28 ± 2.7 after stimulation (n=4; P < 0.05). The controls showed 
the expected pattern. While the repression marks H4K12bio and H3K9me2 were 
removed from the IL-2 gene promoter in response to stimulation with PMA and PHA 
(Fig. 3B and C), the relative enrichment of the activation mark H3K9ac was greater after 
than before gene activation (Fig. 3D). 
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Figure 3. Differential enrichment of histone marks in the IL-2 gene promoter in 
Jurkat cells. Jurkat cells were stimulated with PMA/PHA for 3h. Chromatin was 
immunoprecipitated with antibodies to H4K16bio, H4K12bio, H3K9me2, and H3K9ac 
before and after stimulation with phorbol-12-myristate-13-acetate (PMA) and 
phytohemagglutinin (PHA). qRT-PCR was used to quantify the relative enrichment of IL-
2 promoter sequences. Bars without a common letter are significantly different (n = 5, P 
< 0.05) 
 
 
Biotin dependence: 
 
Previous studies suggest that the abundance of H3K9bio, H3K18bio, H4K8bio, and 
H4K12bio at LTR15, LTR22, and SMVT promoter 1 depends on the concentration of 
biotin in culture media and dietary biotin intake in various model organisms including 
healthy adults (14, 15, 19). Here, we observed a similar scenario for H4K16bio. The 
H4K16bio mark was 13-fold and 4-fold more abundant in the LTR22 locus in cells 
cultured in medium containing 10 nmol/l compared with cells cultured in 0.025 nmol/l, 
and 0.25 nmol/l biotin, respectively (Fig. 4A). Similar patterns were observed for the 
repression marks H4K12bio (Fig. 4B), and H3K9me2 (Fig.4C), while the enrichment of 
H3K9ac was not affected by biotin (Fig. 4D). Consistent with previous observations (14), 
biotin deficiency (i.e., low abundance of H4K16bio at LTRs) de-repressed 
retrotransposons. The abundance of LTR transcripts originating in the U5 region (14) was 
2.9 ± 0.6 in cells cultured in medium containing 0.025 nmol/l, 0.9 ± 0.06 in cells cultured 
in medium containing 0.25 nmol/l, and 0.2 ± 0.02 in cells cultured in medium containing 
10 nmol/l (arbitrary units, n=4, P < 0.05 among all treatment groups). 
40 
 
 
Figure 4. The abundance of H4K16bio at the LTR22 locus depends on the 
concentration of  biotin in culture media. Cells were cultured in biotin-defined media 
for 12 d, and chromatin was precipitated with antibodies to H4K16bio, H4K12bio, 
H3K9me2, and H3K9ac; qRT-PCR was used to quantify the relative enrichment of 
LTR22 sequences. Bars without a common letter are significantly different (n = 4-5, P < 
0.05). 
 
 
The enrichment of H4K16bio, H4K12bio, and H3K9me2 at the SMVT promoter 1 
locus was comparable to that at LTR22, e.g., the H4K16bio mark was 1.7-fold and 1.4-
fold more abundant in cells cultured in medium containing 10 nmol/l compared with cells 
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cultured in 0.025 nmol/l, and 0.25 nmol/l biotin, respectively. However, the differences 
among the different biotin concentrations did not reach statistical significance for the 
SMVT promoter (P = 0.21). 
The efficacy of biotin treatment was confirmed by probing biotinylated 
holocarboxylases with IRDye-streptavidin (Fig. 5, upper gel). Clearly, the abundance of 
holocarboxylases depended on the concentration of biotin in culture media. Equal loading 
of lanes was confirmed by using anti-PC as a probe for total PC (holo & apo; Fig. 5, 
lower gel). 
 
 
Figure 5. Biotinylation of carboxylases depends on the concentration of biotin in 
culture media. Jurkat cells were culture in biotin-defined media for 12 d, and 
carboxylase-bound biotin was probed with IRDye-streptavidin in pyruvate carboxylase 
(PC), 3-methylcrotonyl-CoA carboxylase (MCC), and propionyl-CoA carboxylase (PCC) 
(upper gel). Equal loading of lanes was confirmed by using anti-PC as a probe (lower 
gel). 
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HCS deficiency: 
 
Consistent with a previous report (19), the enrichment of H4K16bio and the 
repression marks H4K12bio and H3K9me2 decreased at the LTR22 locus in HCS-
deficient fibroblasts (WG2215) compared with HCS-normal fibroblasts (IMR-90) (Fig. 6. 
A-C). The same pattern was obtained if H4K16bio was studied at SMVT promoter 1 and 
LTR15 loci (data not shown). HCS activity in both types of fibroblasts was confirmed by 
probing transblots of biotinylated carboxylases with IRDye-streptavidin (Fig. 6D, upper 
gel). Biotinylated carboxylases were easily detectable in IMR-90 fibroblasts, whereas no 
signal was detectable in WG2215 fibroblasts. Anti-PC was used to confirm that the 
decrease of biotinylation signal in WG2215 cells was due to the inability of mutant HCS 
to biotinylate carboxylases rather than low apocarboxylases expression or differences in 
the loading or integrity of the proteins (Fig. 6D, lower gel). 
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Figure 6. The enrichment of H4K16bio at LTR22 depends on HCS in primary 
fibroblasts. (A-C) HCS-normal fibroblasts (IMR-90) and HCS-deficient fibroblasts 
(WG2215) were cultured in medium containing 10 nmol/l biotin. Chromatin was 
precipitated with antibodies to H4K16bio, H4K12bio, and H3K9me2, and qRT-PCR was 
used to quantify the relative enrichment of LTR22. Bars without a common letter are 
significantly different (n = 3-4, P < 0.05). (D) Biotin in PC, MCC, and PCC was probed 
with IRDye-streptavidin (upper gel); equal loading was confirmed by using anti-PC as a 
probe (lower gel). 
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Discussion 
Here, we demonstrate that K16 in human histone is a target for covalent 
biotinylation, and we provide first insights into possible biological functions of 
H4K16bio in pericentromeric heterochromatin and gene repression. A novel antibody 
was generated and its specificity for H4K16bio was demonstrated in an extensive series 
of testing. Importantly, we report that the abundance of the H4K16bio mark depends on 
both biotin supply and HCS activity. 
H4K16bio seems to play an important role in gene regulation, based on the following 
observations. First, the enrichment of H4K16bio in the IL-2 gene promoter greatly 
decreases in response to gene activation with phorbol ester and mitogen; H4K16bio 
depletion co-incides with an increase in the abundance of IL-2 transcript. Second, the 
enrichment of H4K16bio at the retroelement LTR22 depends on the concentration of 
biotin in culture media; H4K16bio depletion co-incides with an increase in the abundance 
of LTR transcript. This observation is particularly important given that previous in-depth 
studies of retroelement repression suggest an increase in chromosomal abnormalities and, 
therefore, cancer risk in biotin-depleted cells (14). Third, the enrichment of H4K16bio in 
the SMVT gene promoter increases in response to biotin supplementation. In previous 
studies we provided evidence that increased biotinylation of histones in the SMVT 
promoter is an important regulatory mechanism to repress the expression of the SMVT 
gene in biotin-supplemented cells (15). It appears that the roles of histone biotinylation in 
gene repression are not specific for distinct biotinylation sites, as all biotinylation sites 
studies to date are overrepresented in transcriptionally repressed chromatin (18, 19). 
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A recent report suggests that some of the commercial antibodies to biotinylated 
histones cross-react with acetylated histones (28). In response to that report, we re-
examined our in-house antibodies to H3K9bio, H3K18bio, H4K8bio, and H4K12bio and 
did not detect any cross-reactivity with acetylation marks {(13), T. Kuroishi et al., in 
preparation}. We propose that these conflicting results are caused by the targets used for 
specificity testing. Healy et al. used recombinant histones that were enzymatically 
acetylated or biotinylated (28); the extent acetylation and biotinylation and the actual 
modification sites (e.g., K8 vs. K12) remained unknown. In contrast, in our studies we 
used synthetic peptides as targets, where both the extent and location of the modification 
were unambiguous {(13), T. Kuroishi et al., in preparation}. However, in contrast with 
the other in-house antibodies, the batch of polyclonal anti-H4K16bio tested here showed 
some cross-reactivity with H4K16ac. It seems prudent to individually validate each batch 
of polyclonal antibodies to biotinylated histones. 
Our studies of histone biotinylation in HCS mutant fibroblasts lend further strength 
to the notion that histone biotinylation is a real phenomenon. The abundance of 
biotinylation marks was substantially lower in HCS mutant WG2215 fibroblasts 
compared with IMR-90 fibroblasts. Similar observations were made in previous studies 
(10, 14, 15), along with the observation that recombinant human HCS and its microbial 
ortholog BirA biotinylate histones in vitro (11, 13). There is still some level of 
uncertainty as to whether effects of HCS on gene regulation are mediated by biotinylation 
of histones or biotinylation of proteins such as carboxylases. However, the phenotypes of 
HCS knockdown are vastly different than phenotypes of carboxylase knockdown (7, 29), 
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suggesting that aberrant biotinylation of histones in HCS-deficient cells impairs gene 
regulation. 
Two recent reports suggest that histone biotinylation is rare, occurring in <0.1% of 
histones (16) or that biotinylation of histones might be an in vitro artifact (28). We agree 
that histone biotinylation is rare, but stress that the abundance of any epigenetic mark 
must not be confused with its importance. For example, only ~3% of cytosines are 
methylated, but the role of DNA methylation in gene regulation is undisputed (30). 
Likewise, phosphorylation of serine-14 in histone H2B and poly(ADP-ribosylation) of 
histones are detectable only after induction of apoptosis and major DNA damage, 
respectively, but the role of these epigenetic marks in cell death is clear (31-33). 
Moreover, low abundance of an epigenetic mark in bulk histone extracts and high 
enrichment at specific loci are not mutually exclusive. Evidence suggests that about one 
out of three histone H4 molecules might be biotinylated at K12 in telomeric repeats (17). 
We conclude that biotinylation of histones H3 and H4 plays important roles in gene 
regulation and genome stability. Further mechanistic studies in whole organisms await 
the arrival of a conditional HCS knockout mouse, which is an ongoing effort in our 
laboratory. 
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CHAPTER 3 
 
A 96-WELL PLATE ASSAY FOR HIGH-THROUGHPUT 
ANALYSIS OF HOLOCARBOXYLASE SYNTHETASE ACTIVITY 
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Introduction 
Holocarboxylase synthetase (HCS, E.C. 6.3.4.10) was identified by Suzuki and co-
workers (1, 2); it catalyzes the covalent attachment of biotin to distinct lysine residues in 
carboxylases (3). Mammalian cells express the following five carboxylases: acetyl-CoA 
carboxylase 1 in the cytoplasm, and acetyl-CoA carboxylase 2, 3-methylcrotonyl-CoA 
carboxylase, propionyl-CoA carboxylase, and 3-methyl-crotonyl-CoA carboxylase in 
mitochondria. Biotinylated carboxylases play essential roles in the metabolism of fatty 
acids, amino acids, and glucose (4, 5). 
HCS also catalyzes the binding of biotin to lysines in histones (6). Histones H3 and 
H4 are better targets for biotinylation than other histones (7, 8), but biotinylation sites 
have been identified in H2A, H3, and H4 (9-11). Biotinylation of histones plays essential 
roles in gene repression and genome stability (12-14). 
Consistent with the important role for HCS as protein biotinyl ligase, the monomeric 
enzyme is widely distributed throughout cells and has been detected in cytoplasm, 
mitochondria, and nuclei in mammalian cells (1, 15, 16). Three splicing variants of HCS 
have been identified in human placenta with molecular weights of 86, 82, and 76 kDa 
(15, 17) but additional variants might exist (1). Nuclear HCS is a chromatin protein (18) 
and appears to be enriched near the nuclear lamina (16). 
To date, no living HCS null individual has been identified, suggesting embryonic 
lethality. HCS knockdown studies (~30% residual activity) produced phenotypes such as 
decreased life span and heat resistance (18) and increased frequency of retrotransposition 
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events in Drosophila melanogaster (13). Numerous mutations in the human HCS gene 
have been identified and characterized at both the enzymatic and clinical level (19, 20). 
Unless diagnosed and treated early, HCS deficiency appears to be uniformly fatal (21). In 
most individuals clinical signs improve if treatment with pharmacological doses on biotin 
is initiated early (19-22). In addition to mutations, about 2,200 single nucleotide 
polymorphisms have been mapped in the HCS locus but their importance for human 
health is unknown (23). 
The prevention of adverse effects of HCS deficiency depends on the early diagnosis 
of enzyme activity. As of today, analysis of HCS activity depends on indirect assays that 
quantify the abundance of biotinylated carboxylases (“multiple carboxylase deficiency”). 
These assays are cumbersome and do not lend themselves to the analysis of a large 
number of samples, as required for studies of enzyme kinetics in HCS-deficient 
individuals. Moreover, our laboratory is interested in the identification of synthetic and 
natural HCS inhibitors that specifically target distinct subcellular structures. Such 
inhibitors would provide useful tools to distinguish biological effects mediated by 
biotinylation of cytoplasmic and mitochondrial carboxylases from those mediated by 
biotinylation of nuclear histones. Here we took an important step towards these goals and 
developed a 96-well assay for high-throughput analysis of both purified HCS and HCS in 
biological samples. 
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Materials and Methods 
Principle of assay 
The assay is based on the HCS-dependent biotinylation of a polypeptide named p67, 
followed by detection and quantification of p67-bound biotin in a 96-well plate format 
using IRDye-streptavidin and infrared spectroscopy. p67 comprises the 67 C-terminal 
amino acids in human propionyl-CoA carboxylase, including the biotin-binding site 
lysine-669, and is a widely accepted substrate in studies of HCS (24). Briefly, a mixture 
(50 µl) of 75 mmol/l Tris-acetate (pH 8.0; all concentrations are final), 7.5 mmol/l ATP, 
0.3 mmol/l dithiothreitol, 0.3 mmol/l biotin, 45 mmol/l MgCl2, 6 nmol/l recombinant 
HCS (rHCS), and 8 µmol/l recombinant p67 was incubated for two hours at 37°C, unless 
noted otherwise (“Results”). Recombinant proteins were stored for up to 6 months 
without appreciable loss of activity; dithiothreitol and ATP were stored in small aliquots 
at -20°C. Reactions were terminated by mixing 40 µl of sample with 60 µl of coating 
buffer containing 50 mmol/l sodium carbonate (pH 9.6) and 200 mmol/l sodium EDTA in 
black 96-well plates (Corning, New York, NY; catalog number 3601); plates were 
incubated over night at 4°C on a rotating shaker. The coating buffer was removed, wells 
were washed twice with distilled water, and blocked with 200 µl of blocking solution 
{0.1% bovine serum albumin (wt./vol) and 0.05% Tween-20 (vol./vol) in phosphate-
buffered saline} for at least 4 h at 4°C. The blocking solution was discarded, and plates 
were washed twice with phosphate-buffered saline and incubated with 100 µl of 
IRDye®-800CW-streptavidin for 1 h on a rotator at room temperature. IRDye-
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streptavidin was prepared by diluting a commercial stock solution (LI-COR, Lincoln, 
NE; catalog number 926-32230; 2.4 moles of IRDye 800 CW/mole of streptavidin, 1 
mg/ml) 4,000-fold in 0.1% Tween 20 in phosphate-buffered saline. Plates were washed 
four times with 0.1%-Tween-20 in phosphate-buffered saline. IRDye fluoresence was 
quantified using the 800CW channel in an infrared imaging system (Odyssey LI-COR; 
Lincoln, NE). HCS- or p67-free samples were used as negative controls. 
  
Recombinant HCS (rHCS) 
A clone of human HCS fused to glutathione S-transferase, S·tag, and 6x his·tag was 
expressed and purified as described (6) with the following modifications. Cells were 
centrifuged at 4ºC (3,000 g for 30 minutes) and precipitated cells were resuspended in 15 
ml of binding buffer {PBS, pH 7.3 (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 
mM KH2PO4, pH 7.3)} with protease inhibitor cocktail (Sigma, St. Louis, MO). Samples 
were sonicated on ice (Branson 250 Digital Sonifier, Danbury, CT) for 7 min with a 10-s 
burst (30% amplitude) alternated with 20-s resting periods. The lysate was centrifuged at 
10,000 g for 10 min at 4ºC. The supernatant was collected and rHCS fusion protein was 
purified by using GSTrap FF columns on an AKTA protein purification system (GE 
Health care; Piscataway, NJ). Protein purity was confirmed by gel electrophoresis and 
staining with coomassie blue; bioactivity of rHCS was tested using gel electrophoresis 
with recombinant p67 as substrate as described (6). p67-free and HCS-free mixes were 
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used as negative controls. Protein concentration was determined using the bicinchoninic 
acid method (Pierce, Rockford, IL). 
 
Expression and purification of p67 
Recombinant p67 was used as substrate for HCS activity assays. His-tagged p67 was 
produced and purified using His Trap FF columns on an AKTA protein purification 
system (GE Healthcare, Piscataway, NJ) as described (8); purity was confirmed by using 
gel electrophoresis and staining with coomassie blue. The microbial HCS ortholog BirA 
is known to biotinylate an appreciable fraction of recombinant p67 (8); hence, the 
biotinylated fraction of recombinant p67 was removed using avidin columns as described 
(8). Protein concentrations were determined using the bicinchoninic acid method. 
 
Assay calibration 
 
Assays were calibrated by preparing dilution series of up to 0.8 nmoles/l of IRDye-
streptavidin in phosphate-buffered saline. One molecule of streptavidin can bind up to 
four molecules of biotin (25), but the true extent of biotin binding in this assay is 
unknown. Hence, the assay was calibrated by assuming that 2 molecules of biotin were 
bound per molecule of streptavidin. Infrared absorbance of IRDye-streptavidin was 
measured at 800 nm (channel 800CW) in the Odyssey imaging system. Non-linear 
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regression analysis was used to calculate Km and Vmax of HCS for p67 (GraphPad Prism 
5.00; La Jolla, CA). 
 
Analysis of HCS in human cells  
 
Whole cell extracts from 150 * 106 Jurkat human lymphoid cells were prepared 
using 500 µl of cold lysis buffer in the presence of protease inhibitors (26). Cells were 
sonicated on ice (Branson 250 Digital Sonifier, Danbury, CT) with a 5-s burst (30% 
amplitude). Complete lysis was confirmed by visual inspection under a light microscope. 
Debris was removed by centrifugation at 1,600 g at 4ºC for 5 min; the supernatant 
contained 17.3 µg/µl total protein. Activity of endogenous HCS was quantified using the 
plate assay by incubating 23 µl of supernatant (~400 µg protein) with cofactors and 
recombinant p67 in a final volume of 50 µl for 2 h at 37°C. Negative controls were 
prepared by omitting supernatant and by supernatants for 2 min at 99°C.  
 
Statistical analysis 
 
Bartlett’s test was used to test for homogeneity of variances (27). Significance of 
differences among more than two groups was tested by one-way ANOVA and Fisher’s 
Protected Least Significant Difference procedure for post hoc testing. Student’s paired t-
test was used for pairwise comparisons. StatView 5.0.1 (SAS Institute, Cary NC, USA) 
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was used to perform all calculations. Differences were considered statistically significant 
if P < 0.05. Data are expressed as mean ± S.D.  
 
Results  
 
Recombinant HCS and p67 
Purified rHCS produced a protein of the expected size (114.6 kDa due to tags) and 
was >90% pure as judged by staining with coomassie blue (Fig. 1A, lane 1). Likewise, 
his-tagged recombinant p67 produced a chemically pure protein of the expected size, 
judged by staining with coomassie blue (Fig. 1A, lane 2). When rHCS was incubated 
with p67 and cofactors, a strong biotinylation signal was detected in p67 using 
streptavidin as probe (Fig. 1A, lane 3), consistent with the notion that rHCS was 
bioactive. Importantly, we confirmed our previous observation that recombinant p67 is 
biotinylated by BirA in E. coli (Fig. 1B, lane 1) and therefore requires affinity 
purification before use. When recombinant p67 was purified by using avidin columns, the 
vast majority of biotinylated p67 was removed (Fig. 1B, lane 2). For all assays described 
below, we used biotin-depleted p67. 
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Fig 1. Recombinant HCS and p67. (A) Recombinant HCS (lane 1) and p67 (lane 2) 
were purified using affinity chromatography and stained with coomassie blue (CB); p67 
was incubated with rHCS and co-factors, and biotin was probed with streptavidin (SA, 
lane 3). (B) Biotinylation of recombinant p67 by microbial BirA was probed with 
streptavidin before and after purification of p67 by avidin chromatography. 
 
Temperature and time  
The catalytic activity of rHCS depended on temperature and time. When various 
amounts of rHCS were incubated with p67 and cofactors at either 4°C or 37°C, enzyme 
activities were significantly higher at 37°C (Fig. 2); representative examples (2.2 nmol/l 
and 5.8 nmol/l rHCS) are depicted. At 4°C, enzyme activities were just above 
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background noise. This is consistent with enzyme-mediated rather than non-enzymatic 
catalysis. All subsequent experiments were conducted at 37°C. 
 
 Fig. 2. Temperature dependency of rHCS. Various amounts of rHCS were incubated 
with p67 and cofactors at 4˚C and 37˚C. Enzyme activities were measured by infrared 
spectroscopy. Bars without a common letter are significantly different for the same 
concentration of rHCS (n=3, P < 0.05). 
 
 
When various amounts of rHCS were incubated with p67 and cofactors for 1, 2, or 3 
h, enzyme activities increased linearly for up to 2 h, but leveled off thereafter. For 
example, enzyme activities (7.2 nmol/l rHCS) were 12.6 ± 2.2 of infrared absorbance 
after 1 h, 28.8 ± 2.9 after 2 h, and 34.1 ± 2.2 after 3 h (Fig. 3). Values are expressed in 
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arbitrary units of infrared absorbance (800 nm) until assay optimization and calibration 
was achieved (see below). All subsequent experiments were conducted using 2-h 
incubations. 
 
Fig. 3. Effect of incubation time on rHCS activity. rHCS was incubated with p67 and 
cofactors for 1, 2 or 3 h at 37°C. Enzyme activity was measured by infrared spectroscopy. 
Bars without a common letter are significantly different (n = 3, P < 0.05) 
 
Concentrations of HCS and p67 
The amount of p67 that was biotinylated in plate assays increased linearly up to a 
concentration of rHCS of 8 nmol/l, and leveled off thereafter (Fig. 4). Subsequent 
experiments were conducted using 6 nmol/l HCS to ensure assay linearity. Furthermore, 
an rHCS dilution series was conducted to determine detection limit of rHCS in this assay. 
At a concentration of 1.08 nmol/l HCS, biotinylation of p67 was significantly greater 
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than in negative controls without rHCS (n = 3, P < 0.05), whereas 0.54 nmol/l HCS were 
not significantly different from background controls (data not shown). 
 
Fig. 4. rHCS concentration. Recombinant p67 was incubated with various 
concentrations of rHCS and cofactors at 37°C for 2 h. Biotinylation of p67 was quantified 
by IRDye-streptavidin and infrared absorbance. 
 
Dose-response studies were conducted with varying amounts of p67 to determine a 
concentration where substrate availability is no longer a limiting factor in this plate assay. 
A linear dose-response was obtained for up to 5.2 µmol/l p67, while p67 was no longer 
rate limiting beyond that concentration (Fig. 5). These findings were further corroborated 
by enzyme kinetics studies. The apparent Km of rHCS for p67 equaled 4.1 ± 1.5 µmol/l 
and the apparent Vmax equaled 34.9 ± 4.1 units of infrared absorbance (Fig.6). For 
subsequent experiments, p67 was used at a concentration of 8 µmol/l. 
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Fig. 5. p67 concentration. Various amounts of recombinant p67 were incubated with 6 
nmol/l rHCS and cofactors at 37°C for 2 h. Biotinylation of p67 was quantified by 
IRDye-streptavidin and infrared absorbance. 
 
Fig 6. Kinetics of p67 biotinylation by rHCS. The line was fitted to the Michaelis-
Menten equation by nonlinear regression analysis (n = 3). 
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Assay calibration 
A dilution series of IRDye-streptavidin was prepared to calibrate the HCS assay. One 
molecule of streptavidin can bind up to four biotin molecules (25); we assumed that each 
molecule of IRDye-streptavidin bound, on average, two molecules of biotin under the 
conditions of this assay. The dilution series of IRDye-streptavidin produced a linear 
response across all concentrations tested (Fig. 7), and the assay system was re-calibrated 
daily. A typical sample of rHCS under the conditions described in the preceding sections 
produced a signal of about 36 units of infrared absorbance, suggesting that 0.16 µmol of 
p67 were biotinylated when incubated with 6 nmol/l HCS for 2 h at 37°C. We define one 
unit of HCS activity as 0.08 µmol of biotinylated p67 formed x nmol/l-1 HCS x h-1 at 
37°C. 
 
Fig. 7. Assay calibration. A standard curve was produced by quantifying the infrared 
absorbance of IRDye-streptavidin (up to 0.8 nmol/well) at 800 nm. Note that 0.8 nmoles 
of IRDye-streptavidin were considered to be the equivalent of 1.6 nmol of biotin/well (n 
= 3).   
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HCS activity in Jurkat cells 
 
Supernatants from Jurkat cells contained 0.14 ± 0.02 µmol of biotinylated p67 
produced per hour in 400 µg of total protein; no signal was detected in cell-free controls 
and heat-treated protein extracts (negative controls). 
 
Discussion 
Here, we present a 96-well plate assay for high-throughput screening of HCS activity 
based on the detection of biotinylated p67 using IRDye-streptavidin and infrared 
absorbance. Previous assays of HCS activity are based on the biotinylation of p67 in a gel 
electrophoresis-based format. While we acknowledge that the gel-based assay is slightly 
more sensitive than the plate assay (not shown), we also note that the plate assay has the 
advantages that large numbers of samples (including replicates) can be analyzed rapidly 
and cost-efficiently. Despite its lower sensitive, analysis of HCS in cell extracts by plate 
assay is feasible, as evidenced by successful quantification of enzyme activity in Jurkat 
cell extracts. Moreover, the plate assay does not require the use of radiochemicals, unlike 
some of the other assays of HCS deficiencies in patients with multiple carboxylase 
deficiency (19). We envision two possible applications for the plate assay. First, the assay 
can be used in the analysis of enzyme kinetics for mutant or variant human HCS, 
including newborn screening. Second, the assay could be particularly useful when 
screening libraries of synthetic or naturally occurring compounds for potential HCS 
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inhibitors in a high-throughput format. With the newly discovered HCS-dependent 
biotinylation of histones and its role in gene regulation and genome stability (12-14, 28), 
the need for robust HCS assays can only increase. 
This study confirmed our previous observations that particular attention needs to be 
paid to the protocols for preparing recombinant p67 and HCS. Recombinant p67 contains 
biotin and requires affinity purification prior to use in HCS assays (8), otherwise 
artificially high activities may be recorded. The yield of bioactive rHCS is low, if 
produced following protocols published in the 1990s, at least in our laboratory. We 
suspect that the low yield of bioactive rHCS by previous protocols is caused by improper 
folding of the protein and devised a protocol tailored towards maximizing the yield of 
rHCS (6). 
One obstacle to the broad use of this 96-well plate assay is its apparent dependence 
on the availability of an infrared spectrophotometer, which may not be available in 
clinical laboratories. If no infrared spectrophotometer is available, we propose modifying 
the assay by substituting streptavidin-peroxidase for IRDye-streptavidin in a standard 
plate reader format at 450 nm. We conclude that a robust method was developed for a 
robust assay of HCS activities in both clinical and research settings. 
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